## ADVANCED MANUFACTURING AND ANALYTIC TECHNOLOGIES (AMAT) IN REGENERATIVE MEDICINE THERAPIES (RMT) WORKSHOP

Tuesday March 14, 2023

## AGENDA

9:00 am – 9:10 am	OPENING REMARKS – Steven Oh, Ph.D.
	<b>CELLULAR THERAPY SESSION*</b> This session also includes discussions of genetically modified CAR T cells
9:10 am – 9:55 am	<b>KEYNOTE ADDRESS:</b> Enabling Quality-by-Design (QbD)-driven Manufacturing of Cell Therapies: The Role of Data Science, In/At-line Process Analytics, and Feedback-controlled Automation; Krishnendu Roy, Ph.D.; Georgia Institute of Technology (Atlanta, GA) <b>(40 min</b> + 5 min Q&A)
9:55 am – 11:10 am	PRESENTATIONS
	<i>i. Manufacturing Mesenchymal Stromal Cells-small Extracellular Vesicles (MSC-sEVs) for Clinical Testing;</i> <b>Sai Kiang Lim</b> , Ph.D.; National University of Singapore; Agency for Science, Technology and Research (A*Star) (Singapore) <b>(20 min + 5 min Q&amp;A)</b>
	ii. Scaling Manufacture of Pluripotent Stem Cell-Based Therapies for Advanced Clinical Development and Eventual Commercialization: Case Study of Development of an Implant for the Treatment of Geographic Atrophy; Jane Lebkowski, Ph.D.; Regenerative Patch Technologies (Portola Valley, CA) (20 min + 5 min Q&A)
	iii.Digital Tools and Adaptive Manufacturing Strategies for Advanced Therapies; Qasim A. Rafiq, Ph.D.; University College London (London, U.K.) (20 min + 5 min Q&A)
11:10 am – 11:20 am	MORNING BREAK
11:20 am – 12:35 pm	TISSUE ENGINEERING SESSION PRESENTATIONS <i>i. Tissue Engineered Medical Products for Nervous System Reconstruction</i> ; D Kacy Cullen, Ph.D.; University of Pennsylvania (Philadelphia, PA) (20 min + 5 min Q&A)
11:20 am – 12:35 pm	<ul> <li>TISSUE ENGINEERING SESSION PRESENTATIONS <ul> <li>Tissue Engineered Medical Products for Nervous System Reconstruction; D Kacy Cullen, Ph.D.; University of Pennsylvania (Philadelphia, PA) (20 min + 5 min Q&amp;A)</li> <li>3D-Printed Biodegradable Scaffolds for the Treatment of Critical-Sized Midfacial Bone Injuries; Warren Grayson, Ph.D.; Johns Hopkins University (Baltimore, MD) (20 min + 5 min Q&amp;A)</li> </ul> </li> </ul>
11:20 am – 12:35 pm	<ul> <li><b>TISSUE ENGINEERING SESSION</b></li> <li><b>PRESENTATIONS</b> <ul> <li><i>i. Tissue Engineered Medical Products for Nervous System Reconstruction</i>; <b>D Kacy Cullen</b>, Ph.D.; University of Pennsylvania (Philadelphia, PA) (20 min + 5 min Q&amp;A)</li> <li><i>ii. 3D-Printed Biodegradable Scaffolds for the Treatment of Critical-Sized Midfacial Bone Injuries</i>; Warren Grayson, Ph.D.; Johns Hopkins University (Baltimore, MD) (20 min + 5 min Q&amp;A)</li> <li><i>iii. Advanced 3D/4D Bioprinting and Nanotechnology for Complex Tissue Regeneration</i>; Lijie Grace Zhang, Ph.D.; George Washington University (Washington, DC) (20 min + 5 min Q&amp;A)</li> </ul> </li> </ul>
11:20 am – 12:35 pm 12:35 pm – 1:05 pm	<ul> <li><b>TISSUE ENGINEERING SESSION</b></li> <li><b>PRESENTATIONS</b> <ol> <li>Tissue Engineered Medical Products for Nervous System Reconstruction; D Kacy Cullen, Ph.D.; University of Pennsylvania (Philadelphia, PA) (20 min + 5 min Q&amp;A)</li> <li>3D-Printed Biodegradable Scaffolds for the Treatment of Critical-Sized Midfacial Bone Injuries; Warren Grayson, Ph.D.; Johns Hopkins University (Baltimore, MD) (20 min + 5 min Q&amp;A)</li> <li>Advanced 3D/4D Bioprinting and Nanotechnology for Complex Tissue Regeneration; Lijie Grace Zhang, Ph.D.; George Washington University (Washington, DC) (20 min + 5 min Q&amp;A)</li> </ol> </li> <li><b>CELLULAR THERAPY AND TISSUE ENGINEERING PANEL DISCUSSION</b> Krishnendu Roy; Sai Kiang Lim; Jane Lebkowski; Qasim Rafiq; D Kacy Cullen; Warren Grayson; Lijie Grace Zhang</li></ul>

1:55 pm – 2:40 pm	GENE THERAPY: VIRAL VECTORS SESSION KEYNOTE ADDRESS: AAV Vector Production, Evolution of a Process; Jude Samulski, Ph.D.; University of North Carolina (Chapel Hill, NC) (40 min + 5 min Q&A)
2:40 pm – 3:55 pm	PRESENTATIONS
	<ul> <li>Overcoming AAV CMC challenges through the use of platform-based approaches to streamline AAV-based drug development; Steven Gray, Ph.D.; University of Texas Southwestern Medical Center (Dallas, TX) (20 min + 5 min Q&amp;A)</li> </ul>
	ii. Directed Evolution of EnhaAAV Delivery Systems for Clinical Gene Therapy; David V. Schaffer, Ph.D.; University of California, Berkeley (Berkeley, CA) (20 min + 5 min Q&A)
	iii. Gene Therapy for Prevalent Diseases: Strategies to improve AAV titer and quality; Ali Aghajanirefah, Ph.D.; Adverum Biotechnologies Inc (San Francisco, CA) (20 min + 5 min Q&A)
3:55 pm – 4:25 pm	GENE THERAPY: VIRAL VECTORS PANEL DISCUSSION Jude Samulski, Steven Gray, David V. Schaffer, Ali Aghajanirefah
4:25 pm – 4:30 pm	CLOSING REMARKS